An Open-Label, Single-Arm, Multicenter, Prospective, Phase 4, Interventional, Flexible Dose Study to Evaluate the Effectiveness of Vortioxetine on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder
Phase of Trial: Phase IV
Latest Information Update: 16 Feb 2018
At a glance
- Drugs Vortioxetine (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Takeda
- 12 Feb 2018 Status changed from active, no longer recruiting to completed.
- 04 Feb 2018 Planned end date changed from 31 Jan 2018 to 12 Feb 2018.
- 04 Feb 2018 Planned primary completion date changed from 31 Jan 2018 to 12 Feb 2018.